Topic

Feliza Mirasol is the science editor for 

Articles

uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.

uBriGene Expands into US Market with Acquisition of Mustang Bio's CGT Manufacturing Facility

With $73 million in financing from investment firms, Myeloid Therapeutics plans to accelerate its lead clinical candidate into Phase I/II development for treating solid tumors.

Myeloid Therapeutics Gets $73 Million to Advance mRNA-based Pipeline

Grant Playter is the Assistant Editor for 

Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.

The United States and the Global BioPharma Market

Chris Spivey is the editorial director of 

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

How mRNA will Shift Pharma Commercial Models with Jane True, Pfizer

Sania Therapeutics has emerged from stealth mode and launched its technology platforms for enabling the development of novel therapeutics to treat neural circuit dysfunction.

Launch of Sania Therapeutics Expected to Advance Development of Novel Therapeutics for Neural Circuit Dysfunction

Biotech firm Lumen Bioscience has received fast track designation from FDA for its oral biologic drug candidate for treating C. difficile infection.

FDA Grants Lumen Bioscience Fast Track Designation for Oral Biologic

Editor of Pharmaceutical Technology Europe

Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.

Waters Set for Growth in Bioanalytical Characterization with Wyatt Acquisition

Gilead Sciences and Arcus Biosciences have expanded their research collaboration to include inflammatory diseases in addition to oncology. 

Gilead Sciences and Arcus Biosciences Expand Research Partnership

Astellas and Sony will collaborate to discover a novel ADC platform for use in oncology.

Astellas and Sony Enter ADC Platform Collaboration

In a brief, the Federal Trade Commission cited concerns about the acquisition resulting in an increased monopoly on Amgen’s newly acquired thyroid eye disease and chronic refractory gout treatments.

BioBusiness